<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665702</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO-SH-001</org_study_id>
    <nct_id>NCT02665702</nct_id>
  </id_info>
  <brief_title>Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas</brief_title>
  <official_title>Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas of the Prospective, Single Arm Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to explore whether endostar combined with NVB and DDP as treatment
      could improve progression-free surial time (PFS) and to evaluate the safety of the
      chemotherapy regimens
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to explore whether endostar combined with NVB and DDP as treatment could
      improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy
      regimens used as second-line treatment of advanced esophageal squamous cell carcinomas
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Endostar Combined With NVB and DDP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVB</intervention_name>
    <description>25mg/m2 ，D1，8</description>
    <arm_group_label>Endostar Combined With NVB and DDP</arm_group_label>
    <other_name>Vinorelbine Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDP</intervention_name>
    <description>75mg/m2 ，D1 or 25mg/m2 D1-3</description>
    <arm_group_label>Endostar Combined With NVB and DDP</arm_group_label>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>15mg/d，d1-d7 civ</description>
    <arm_group_label>Endostar Combined With NVB and DDP</arm_group_label>
    <other_name>endo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven primary thoracic esophageal squamous cell carcinoma

          2. According to the esophageal AJCC2009 7th to determine new stage IV esophageal cancer

          3. The subject has PD after first-line chemotherapy or radiation within a year

          4. Presence of at least one index lesion measurable by CT scan or MRI according to RECIST
             1.1

          5. Can eat more than liquid diet; No signs before esophageal perforation

          6. 18~75 years

          7. PS:0-1

          8. Life expectancy of ≥ 3 months

          9. ANC ≥ 2×109/L，PLT ≥ 100×109/L，Hb ≥ 90g/L

         10. TB ≤ UNL； ALT/AST ≤ 2.5×UNL，AKP ≤ 5×UNL

         11. Ccr≤ UNL,Scr≥60 mL/min

         12. Normal electrocardiogram (ecg), the body had no unheal wounds

         13. Radiotherapy before within the scope of the normal dose and not affect subsequent
             treatment

         14. Prior to biological agents, especially e. coli genetically engineered products without
             severe allergic reactions

         15. Signed written informed consent

        Exclusion Criteria:

          1. Breast-feeding or pregnant women, no effective contraception if risk of conception
             exists

          2. Chronic diarrhea, enteritis, intestine obstruction which are not under control

          3. Esophageal obstruction cannot eat liquid completely, esophagus have deep ulcer
             perforation or hematemesis; Esophageal cancer common complications such as anastomotic
             leakage, serious lung complications, etc.

          4. A second primary tumor (except skin basal cell carcinoma)

          5. The original serious heart disease, including: higher risk of congestive heart
             failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe
             valvular heart disease, and resistant hypertension

          6. With uncontrol nerve, mental illness or mental disorders, compliance is poor, can't
             cooperate with accounts and response to treatment; Primary brain tumors or CNS
             metastases illness did not get a control, has obvious cranial hypertension or nerve
             mental symptoms

          7. With bleeding tendency

          8. Has inherited bleeding evidence of physical or blood coagulation disorder

          9. With clear chemotherapy drug allergy

         10. Other researchers believe that patients should not participate in this testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chang jian Hua, PD</last_name>
    <phone>13916619284</phone>
    <email>changjianhua@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang jian hua, PD</last_name>
      <phone>13916619284</phone>
      <email>changjianhua@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>January 24, 2016</last_update_submitted>
  <last_update_submitted_qc>January 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chang Jian Hua</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

